Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Lung Neoplasms 16Small Cell Lung Carcinoma 10Breast Neoplasms 8Esophageal Neoplasms 5Sarcoma 4Neoplasms 4Melanoma 4Colorectal Neoplasms 4Advanced Lung Cancer 4Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Thoracic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma of Lung 2Widespread Small Cell Lung Cancer 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Uncommon Pathological Types of Lung Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Lung Cancer 1

Interventions

toripalimab 1pelcitoclax 1osimertinib 1Pemetrexed 1Paclitaxel 1Injections 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EGFR Positive Non-small Cell Lung Cancer × Injections × Thoracic × Clear all
NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
80 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡